Latest news

• Opioid analgesics

  Pfizer's Embeda combines morphine and naltrexone in a single extended-release capsule. ... This, combined with the post-marketing data, suggest that Embeda is providing much-needed pain relief in this patient population without exposure to the risk of

• Pfizer to buy King for $3.6bn

  sprains and bruises; and Embeda (morphine sulphate/ naltrexone hydrochloride), which was approved in August of this year as the first long-acting opioid that is designed to reduce drug liking and

• King's profits hit by generic competition

  Its pain drug Embeda (morphine sulfate and naltrexone hydrochloride) is showing continued growth since it launched in September 2010 and reaped $15m during the second quarter.

• Clouded vision

  EMBEDA (King Pharmaceuticals). Moderate to severe chronic pain . US. Oxycodone hydrochloride.

• King Pharma announce unexpected profit

  The company is currently focusing on gaining regulatory approvals for its trio of opioid products for treating late-stage pain: Remoxy, an extended-release oxycodone drug, Embeda, an extended-release morphine